In rats with cysteamine-induced colon lesions, BPC‑157 given in any of the regimens inhibited the lesions at all time points assessed.
In plain wordsIn rats with colon lesions caused by cysteamine, BPC‑157 reduced the lesions.
- Peptide
- BPC-157
- Outcome
- DecreaseCysteamine colon lesions
- Study
ratn: not reported in source
cysteamine-induced colon lesions- Outcome group
- Gastrointestinal protection · Gastrointestinal
- Studied dose
- 10 µg/kg or 10 ng/kg · intraperitoneal, intragastric or intrarectalAs given in this study (rat).
Source sentences
Pentadecapeptide BPC 157 (10 microg or 10 ng/kg b.w.), given in either regimen, previously shown to have, besides others, a particular beneficial activity just in the intestinal mucosa, inhibited these cysteamine colon lesions (assessed after 30 min, 60 min, 180 min, 24 h, 48 h, 72 h following cyste…
2 context sentences(design, population, supporting numbers)
Intrarectal administration of the cysteamine (200 or 400 mg/kg b.w) produced severe colon lesions (i.e. transmural inflammation with serosal involvement) in rats (30 min-72 h-experimental period), apparently distinctive from smaller lesions after non-specific irritant enema [diluted HCl solution, pH…
All of the tested antiulcer agents were applied simultaneously with cysteamine enema (8 cm from the anus, in a volume of the 1.0 ml/rat) intraperitoneally (i.p.), intragastrically (i.g.) or intrarectally (i.r.).